Brief: Actinium Announces Positive Pivotal Phase 3 Sierra Trial Results Of Iomab-B
27/04/2023 16:36
April 27 (Reuters) - Actinium Pharmaceuticals Inc:
* ACTINIUM ANNOUNCES POSITIVE PIVOTAL PHASE 3 SIERRA TRIAL
RESULTS
OF IOMAB-B SHOWCASED TO THE EUROPEAN TRANSPLANT COMMUNITY IN
ORAL PRESENTATION AT THE EUROPEAN SOCIETY FOR BLOOD AND MARROW
TRANSPLANTATION (EBMT) ANNUAL MEETING
* ACTINIUM PHARMACEUTICALS INC - IOMAB-B MET SIERRA TRIAL
PRIMARY
ENDPOINT
* ACTINIUM PHARMACEUTICALS INC- IOMAB-B MET SIERRA TRIAL
PRIMARY
ENDPOINT AND HAD A FAVORABLE SAFETY PROFILE COMPARED TO CONTROL
ARM
* ACTINIUM : 92% 1-YEAR SURVIVAL, 60% 2-YEAR SURVIVAL IN
PATIENTS
ACHIEVING DCR, MEDIAN OVERALL SURVIVAL HAS NOT BEEN REACHED IN
THESE PATIENTS IN STUDY
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities